non-small cell lung cancer
Conditions
Interventions
control group:PD-1 inhibitor
experimental group:PD-1 inhibitor plus baicalin combination
Sponsors
Beijing Friendship hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The minimum age of the subjects is 45 and the maximum age is 70; 2. The subject must have histologically or cytologically confirmed non-small cell lung cancer that is not suitable for radical treatment, and is receiving PD-1 immunotherapy; 3. According to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, subjects must have at least 1 measurable lesion that has not previously received radiotherapy or other locoregional therapy; 4. The subject's Eastern Cooperative Oncology Group (ECOG) status must be 0 or 1; 5. Subjects must sign an ICF (Informed Consent Form) indicating that they understand the purpose and required procedures of the study and are willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1. The subject has undergone major surgery within 4 weeks prior to signing the ICF (eg requiring general anesthesia, or not fully recovering from surgery, or planning to undergo surgery during the expected study period); 2. The subjects are known to have heart, brain, kidney and other important organ diseases; 3. The subject is known to suffer from mental illness and unconsciousness; 4. Subjects have received an investigational drug within 3 months prior to randomization or are currently participating in a clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor size; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune cells and related functional factors;gut microbiota; | — |
Countries
China
Contacts
Public ContactYan Dan
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed